Oncolytic Virotherapy最新文献

{"title":"The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.","authors":"Hong-My Nguyen, Dipongkor Saha","doi":"10.2147/OV.S268426","DOIUrl":"10.2147/OV.S268426","url":null,"abstract":"<p><p>Glioblastoma (GBM) is a lethal primary malignant brain tumor with no current effective treatments. The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex viruses (oHSVs) as a promising treatment option for GBM. Since the generation and testing of the first genetically engineered oHSV in glioma in the early 1990s, oHSV-based therapies have shown a long way of great progress in terms of anti-GBM efficacy and safety, both preclinically and clinically. Here, we revisit the literature to understand the recent advancement of oHSV in the treatment of GBM. In addition, we discuss current obstacles to oHSV-based therapies and possible strategies to overcome these pitfalls.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"10 ","pages":"1-27"},"PeriodicalIF":6.7,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/30/50/ov-10-1.PMC7917312.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25427629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.","authors":"Laura V Ashton,&nbsp;Barbara Graham,&nbsp;Maryam F Afzali,&nbsp;Daniel Gustafson,&nbsp;Amy L MacNeill","doi":"10.2147/OV.S252727","DOIUrl":"https://doi.org/10.2147/OV.S252727","url":null,"abstract":"<p><strong>Purpose: </strong>Rhabdomyosarcomas (RMS) are difficult tumors to treat with conventional therapies. Publications indicate that oncolytic virotherapy (OV) could benefit cancer patients with tumors that are refractory to conventional treatments. It is believed that the efficacy of OV can be enhanced when used in combination with other treatments. This study evaluated the response of mice with aggressive alveolar RMS (ARMS) allografts to treatment with an OV [recombinant myxoma virus (MYXVΔserp2)] in combination with a Janus kinase (JAK) inhibitor (oclacitinib). Oclacitinib is known to inhibit JAK1 and JAK2 cell signaling pathways, which should limit the antiviral Type I interferon response. However, oclacitinib does not inhibit immune pathways that promote antigen presentation, which help stimulate an anti-cancer immune response.</p><p><strong>Materials and methods: </strong>To determine if MYXVΔserp2 and oclacitinib could improve outcomes in animals with ARMS, nude mice were inoculated subcutaneously with murine ARMS cells to establish tumors. Immune responses, tumor growth, and clinical signs in mice treated with combination therapy were compared to mice given placebo therapy and mice treated with OV alone.</p><p><strong>Results: </strong>Combination therapy was safe; no viral DNA was detected in off-target organs, only within tumors. As predicted, viral DNA was detected in tumors of mice given oclacitinib and MYXVΔserp2 for a longer time period than mice treated with OV alone. Although tumor growth rates and median survival times were not significantly different between groups, clinical signs were less severe in mice treated with OV.</p><p><strong>Conclusion: </strong>Our data indicate that MYXVΔserp2 treatment benefits mice with ARMS by reducing clinical signs of disease and improving quality of life.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"9 ","pages":"17-29"},"PeriodicalIF":6.7,"publicationDate":"2020-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S252727","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38054794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virus-Receptor Interactions and Virus Neutralization: Insights for Oncolytic Virus Development.","authors":"Nadishka Jayawardena, John T Poirier, Laura N Burga, Mihnea Bostina","doi":"10.2147/OV.S186337","DOIUrl":"10.2147/OV.S186337","url":null,"abstract":"<p><p>Oncolytic viruses (OVs) are replication competent agents that selectively target cancer cells. After penetrating the tumor cell, viruses replicate and eventually trigger cell lysis, releasing the new viral progeny, which at their turn will attack and kill neighbouring cells. The ability of OVs to self-amplify within the tumor while sparing normal cells can provide several advantages including the capacity to encode and locally produce therapeutic protein payloads, and to prime the host immune system. OVs targeting of cancer cells is mediated by host factors that are differentially expressed between normal tissue and tumors, including viral receptors and internalization factors. In this review article, we will discuss the evolution of oncolytic viruses that have reached the stage of clinical trials, their mechanisms of oncolysis, cellular receptors, strategies for targeting cancers, viral neutralization and developments to bypass virus neutralization.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"9 ","pages":"1-15"},"PeriodicalIF":6.7,"publicationDate":"2020-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/3f/ov-9-1.PMC7064293.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37748410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Induced Syncytia Formation on the Oncolytic Potential of Myxoma Virus.","authors":"Chase Burton,&nbsp;Mee Y Bartee,&nbsp;Eric Bartee","doi":"10.2147/OV.S220420","DOIUrl":"https://doi.org/10.2147/OV.S220420","url":null,"abstract":"<p><strong>Introduction: </strong>Cancer has become one of the most critical health issues of modern times. To overcome the ineffectiveness of current treatment options, research is being done to explore new therapeutic modalities. One such novel treatment is oncolytic virotherapy (OV) which uses tumor tropic viruses to specifically target and kill malignant cells. While OV has shown significant promise in recent clinical trials, the therapeutic use of viruses poses a number of unique challenges. In particular, obtaining effective viral spread throughout the tumor microenvironment remains problematic. Previous work has suggested this can be overcome by forcing oncolytic viruses to induce syncytia formation.</p><p><strong>Methods: </strong>In the current work, we generated a series of recombinant myxoma viruses expressing exogenous fusion proteins from other viral genomes and examined their therapeutic potential in vitro and in vivo.</p><p><strong>Results: </strong>Similar to previous studies, we observed that the expression of these fusion proteins during myxoma infection induced the formation of multinucleated syncytia which increased viral spread and lytic potential compared to non-fusogenic controls. Contrary to expectations, however, the treatment of established tumors with these viruses resulted in decreased therapeutic efficacy which corresponded with reduced viral persistence.</p><p><strong>Discussion: </strong>These findings indicate that enhanced viral spread caused by syncytia formation can actually reduce the efficacy of OV and supports a number of previous works suggesting that the in vitro properties of viruses frequently fail to predict their in vivo efficacy.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"8 ","pages":"57-69"},"PeriodicalIF":6.7,"publicationDate":"2019-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S220420","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37468542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virus-Receptor Interactions: Structural Insights For Oncolytic Virus Development.","authors":"Nadishka Jayawardena,&nbsp;Laura N Burga,&nbsp;John T Poirier,&nbsp;Mihnea Bostina","doi":"10.2147/OV.S218494","DOIUrl":"https://doi.org/10.2147/OV.S218494","url":null,"abstract":"<p><p>Recent advancements in oncolytic virotherapy commend a special attention to developing new strategies for targeting cancer cells with oncolytic viruses (OVs). Modifications of the viral envelope or coat proteins serve as a logical mean of repurposing viruses for cancer treatment. In this review, we discuss how detailed structural knowledge of the interactions between OVs and their natural receptors provide valuable insights into tumor specificity of some viruses and re-targeting of alternate receptors for broad tumor tropism or improved tumor selectivity.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"8 ","pages":"39-56"},"PeriodicalIF":6.7,"publicationDate":"2019-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S218494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41207884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma","authors":"Juri Kiyokawa, H. Wakimoto","doi":"10.2147/OV.S196403","DOIUrl":"https://doi.org/10.2147/OV.S196403","url":null,"abstract":"Abstract Replication conditional oncolytic human adenovirus has long been considered a promising biological therapeutic to target high-grade gliomas (HGG), a group of essentially lethal primary brain cancer. The last decade has witnessed initiation and some completion of a number of Phase I and II clinical investigations of oncolytic adenovirus for HGG in the US and Europe. Results of these trials in patients are pivotal for not only federal approval but also filling an existing knowledge gap that primarily derives from the stark differences in permissivity to human adenovirus between humans and preclinical mouse models. DNX-2401 (Delta-24-RGD), the current mainstream oncolytic adenovirus with modifications in E1A and the fiber, has been shown to induce impressive objective response and long-term survival (>3 years) in a fraction of patients with recurrent HGG. Responders exhibited initial enlargement of the treated lesions for a few months post treatment, followed by shrinkage and near complete resolution. In accord with preclinical research, post-treatment specimens revealed virus-mediated alteration of the immune tumor microenvironment as evidenced by infiltration of CD8+ T cells and M1-polarized macrophages. These findings are encouraging and together with further information from ongoing studies have a potential to make oncolytic adenovirus a viable option for clinical management of HGG. This review deals with this timely topic; we will describe both preclinical and clinical development of oncolytic adenovirus therapy for HGG, summarize updated knowledge on clinical trials and discuss challenges that the field currently faces.","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"8 1","pages":"27 - 37"},"PeriodicalIF":6.7,"publicationDate":"2019-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S196403","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44741146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Directed evolution as a tool for the selection of oncolytic RNA viruses with desired phenotypes.","authors":"Sergei S Zainutdinov, Galina V Kochneva, Sergei V Netesov, Peter M Chumakov, Olga V Matveeva","doi":"10.2147/OV.S176523","DOIUrl":"10.2147/OV.S176523","url":null,"abstract":"<p><p>Viruses have some characteristics in common with cell-based life. They can evolve and adapt to environmental conditions. Directed evolution can be used by researchers to produce viral strains with desirable phenotypes. Through bioselection, improved strains of oncolytic viruses can be obtained that have better safety profiles, increased specificity for malignant cells, and more efficient spread among tumor cells. It is also possible to select strains capable of killing a broader spectrum of cancer cell variants, so as to achieve a higher frequency of therapeutic responses. This review describes and analyses virus adaptation studies performed with members of four RNA virus families that are used for viral oncolysis: reoviruses, paramyxoviruses, enteroviruses, and rhabdoviruses.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"8 ","pages":"9-26"},"PeriodicalIF":6.7,"publicationDate":"2019-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e2/34/ov-8-9.PMC6636189.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41207883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A cautionary note on the selectivity of oncolytic poxviruses.","authors":"Bingtao Tang,&nbsp;Zong Sheng Guo,&nbsp;David L Bartlett,&nbsp;Jia Liu,&nbsp;Grant McFadden,&nbsp;Joanna L Shisler,&nbsp;Edward J Roy","doi":"10.2147/OV.S189832","DOIUrl":"https://doi.org/10.2147/OV.S189832","url":null,"abstract":"<p><strong>Background: </strong>Oncolytic viruses selectively infect cancer cells while avoiding infection of normal cells. Usually, selectivity is demonstrated by injecting a virus into tumor-bearing mice and observing infection and lysis of tumor cells without infection of other tissues. The general view is that this selectivity is due to tropisms of the virus. However, apparent selectivity could be due to accessibility. For example, intravenously injected virus may not gain access to cells within the central nervous system (CNS) because of the blood-brain barrier.</p><p><strong>Purpose: </strong>We tested the CNS safety of two oncolytic poxviruses that have been demonstrated to be safe for treatment of peripheral tumors (vaccinia virus vvDD-IL15-Rα and myxoma virus vMyx-IL15Rα-tdTr).</p><p><strong>Methods: </strong>Two poxviruses were tested for selectivity in vitro and in vivo.</p><p><strong>Results: </strong>Both viruses infected glioma cells in vitro. In vivo, both viruses infected glioma cells and did not infect neurons when injected into a tumor or into the normal striatum. However, viral gene expression was observed in ependymal cells lining the ventricles, implying that these poxviruses were not as selective as originally predicted. For vvDD-IL15-Rα, some tumor-bearing mice died soon after virus treatment. If the same titer of vvDD-IL15-Rα was injected directly into the lateral cerebral ventricle of nontumor-bearing mice, it was uniformly fatal. Infection of ependymal cells, subventricular cells, and meninges was widespread. On the other hand, vMyx-IL15Rα-tdTr only transiently infected ependymal cells and was safe even when injected directly into the lateral cerebral ventricles. The two poxviruses also differed in their infection of dendritic cells; vvDD-IL15-Rα infected dendritic cells and lysed them but vMyx-IL15Rα-tdTr did not.</p><p><strong>Conclusion: </strong>Vaccinia virus vvDD-IL15-Rα is very promising for treating cancer types outside of the brain. However, for cancers located within the brain, myxoma virus vMyx-IL15Rα-tdTr offers a safer alternative.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"8 ","pages":"3-8"},"PeriodicalIF":6.7,"publicationDate":"2019-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S189832","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36999848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum].","authors":"Hani M. Babiker,&nbsp;Irbaz Bin Riaz,&nbsp;Muhammad Husnain,&nbsp;Mitesh J. Borad","doi":"10.2147/OV.S196145","DOIUrl":"https://doi.org/10.2147/OV.S196145","url":null,"abstract":"<p><p>[This corrects the article on p. 11 in vol. 6, PMID: 28224120.].</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"8 ","pages":"1"},"PeriodicalIF":6.7,"publicationDate":"2019-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S196145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36864602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and applications of oncolytic Maraba virus vaccines.","authors":"Jonathan G Pol,&nbsp;Matthew J Atherton,&nbsp;Byram W Bridle,&nbsp;Kyle B Stephenson,&nbsp;Fabrice Le Boeuf,&nbsp;Jeff L Hummel,&nbsp;Chantal G Martin,&nbsp;Julia Pomoransky,&nbsp;Caroline J Breitbach,&nbsp;Jean-Simon Diallo,&nbsp;David F Stojdl,&nbsp;John C Bell,&nbsp;Yonghong Wan,&nbsp;Brian D Lichty","doi":"10.2147/OV.S154494","DOIUrl":"10.2147/OV.S154494","url":null,"abstract":"<p><p>Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the induction of both innate and adaptive antitumor immunity. To further expand tumor-specific T-cell effector and long-lasting memory compartments, we introduced the MG1 virus in a prime-boost cancer vaccine strategy. To this aim, a replication-incompetent adenoviral [Ad] vector together with the oncolytic MG1 have each been armed with a transgene expressing a same tumor antigen. Immune priming with the Ad vaccine subsequently boosted with the MG1 vaccine mounted tumor-specific responses of remarkable magnitude, which significantly prolonged survival in various murine cancer models. Based on these promising results, we validated the safety profile of the Ad:MG1 oncolytic vaccination strategy in nonhuman primates and initiated clinical investigations in cancer patients. Two clinical trials are currently under way (NCT02285816; NCT02879760). The present review will recapitulate the discoveries that led to the development of MG1 oncolytic vaccines from bench to bedside.</p>","PeriodicalId":19491,"journal":{"name":"Oncolytic Virotherapy","volume":"7 ","pages":"117-128"},"PeriodicalIF":6.7,"publicationDate":"2018-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OV.S154494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36773094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}